Safety and Efficacy of Finerenone in Metabolic Dysfunction Associated Steatotic Liver Disease(MASLD/NAFLD) Related Cirrhosis Patients With Ascites in Prevention of Chronic Kidney Disease.
2. Patient of MASLD/ NAFLD cirrhosis with clinical ascites
3. Stable eGFR-(\>60 ml/min/1.73m2) calculated using MDRD-6 equation: eGFR (ml/min/1.73 m2) = 170 × (Scr)-0.999 × (Age)-0.176 × (0.762 if patient is female) × (1.180 if black) × (SUN)-0.170 × (Albumin)0.318
You may not be if
1. Age \<18 years \>80 years
2. K/C/O systemic hypertension.
3. Coagulopathy- INR \>2.5
4. Post TIPS
5. CTP class C
6. Any intrinsic/structural kidney disease.
7. Refractory Ascites
8. Patient with HCC(outside MILAN criteria) or portal vein thrombosis
9. Pregnancy or Lactating mother
10. Receiving cytotoxic therapy, immunosuppressive therapy or other immunotherapy for primary or secondary renal disease within 6 months prior to enrolment
11. Patients with anuria, acute renal failure, or Addison's disease
12. Heart failure (NYHA II to IV)
13. History of hospitalization for hyperkalaemia or acute renal failure induced by previous aldosterone antagonist treatment
14. Ongoing drug or alcohol abuse
15. Uncontrolled type 2 DM ( HbA1C \> 9)
16. MI, unstable angina, stroke or transient ischemic attack (TIA) within 12 weeks prior to enrolment
17. Coronary revascularization (percutaneous coronary intervention \[PCI\] or coronary artery bypass grafting \[CABG\]) or valvular repair/replacement within 12 weeks prior to enrolment or is planned to undergo any of these procedures after randomisation
18. Diagnosed Mixed ascites (additional etiology of ascites apart from portal hypertension)
19. Patients who are on spirinolactone with stable ascites in the past 12 weeks
20. Refusal to give consent
Clareo Health | Safety and Efficacy of Finerenone in Metabolic Dysfunction Associated Steatotic Liver Disease(MASLD/NAFLD) Related Cirrhosis Patients With Ascites in Prevention of Chronic Kidney Disease.
